Clinical Investigator and Nursing Perspectives on the Management of Common Cancers

FA C U L T Y  I N T E R V I E W S
Emily Olson, MSN, RN, CNP
Denise A Yardley, MD

E D I T O R
Neil Love, MD

Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/ONUBreast115
Follow us at Facebook.com/ResearchToPractice Follow us on Twitter @DrNeilLove
OVERVIEW OF ACTIVITY
Breast cancer is one of the most rapidly evolving fields in oncology nursing and remains a challenge for many healthcare professionals. Furthermore, recent clinical research gains have made an abundance of treatment options available to patients with breast cancer, and published results from ongoing clinical trials continually lead to the emergence of new therapeutic regimens and changes in the use of existing treatments. To provide oncology nurses with the knowledge, information and strategies they can use to address the disparate needs of patients, this issue of the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with breast cancer. Upon completion of this CNE activity, oncology nurses should be able to better counsel and educate patients while developing up-to-date approaches for the management of this disease.

PURPOSE STATEMENT
To present the most current research developments in breast cancer and to provide the perspectives of a clinical investigator and nurse practitioner on the diagnosis and treatment of this disease.

LEARNING OBJECTIVES
• Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
• Develop a plan to manage the side effects associated with systemic therapies to support quality of life and continuation of treatment.
• Recall the recent FDA approval of neoadjuvant pertuzumab, and consider this therapeutic approach when evaluating appropriate patients with HER2-positive early breast cancer.
• Develop an evidence-based algorithm for the initial and long-term treatment of localized and advanced estrogen receptor-positive breast cancer.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by Research To Practice during the period of July 2015 through July 2016.

FOR SUCCESSFUL COMPLETION
This is an audio CNE program. This booklet contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/ONUBreast115 also includes links to relevant abstracts and full-text articles.

To receive credit, participants should read the learning objectives and faculty disclosures, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/ONUBreast115/CNE. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 75% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

This activity is supported by educational grants from Genentech BioOncology and Novartis Pharmaceuticals Corporation.

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

If you would like to discontinue your complimentary subscription to Oncology Nursing Update, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
SELECT PUBLICATIONS


QUESTIONS (PLEASE CIRCLE ANSWER):

1. The Phase III CLEOPATRA trial evaluated a combination of docetaxel and trastuzumab with or without ____________ for patients with previously untreated HER2-positive metastatic breast cancer.
   a. T-DM1
   b. Pertuzumab
   c. Lapatinib

2. Which of the following is a potential toxicity of everolimus?
   a. Colitis
   b. Pancreatitis
   c. Noninfectious pneumonitis

3. Which of the following adverse events may be associated with trastuzumab?
   a. Cardiotoxicity
   b. Pneumonitis
   c. Hepatotoxicity

4. Women receiving tamoxifen for the treatment or prevention of recurrence of breast cancer should avoid antidepressants that are metabolized through the CYP2D6 pathway.
   a. True
   b. False

5. Common side effects that may be experienced by women receiving aromatase inhibitors include which of the following?
   a. Hot flashes
   b. Loss of bone density
   c. Joint pain
   d. Vaginal dryness
   e. All of the above

6. T-DM1-related thrombocytopenia can be managed by dose interruptions.
   a. True
   b. False

7. The FDA recently granted accelerated approval to pertuzumab in combination with trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage breast cancer.
   a. True
   b. False

8. T-DM1 is an antibody-drug conjugate that combines a chemotherapy agent called emtansine with ____________.
   a. Trastuzumab
   b. Docetaxel
   c. Paclitaxel
EDUCATIONAL ASSESSMENT AND CREDIT FORM

Oncology Nursing Update Breast Cancer Edition — Issue 1, 2015

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

<table>
<thead>
<tr>
<th></th>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy of everolimus in combination with exemestane for advanced estrogen receptor-positive, HER2-negative breast cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Incidence, prevention and management of side effects associated with T-DM1 in the treatment of HER2-positive breast cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Activity of pertuzumab in the neoadjuvant setting for HER2-positive breast cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Clinical strategies to manage adverse events associated with everolimus</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Practice Setting:
☐ Academic center/medical school  ☐ Community cancer center/hospital  ☐ Group practice
☐ Solo practice  ☐ Government (eg, VA)  ☐ Other (please specify) ..................

Approximately how many new patients with breast cancer do you see per year? .................. patients

Was the activity evidence based, fair, balanced and free from commercial bias?
☐ Yes  ☐ No
If no, please explain:..........................................................................................................

Will this activity help you improve patient care?
☐ Yes  ☐ No  ☐ Not applicable
If yes, how will it help you improve patient care? .............................................................

Did the activity meet your educational needs and expectations?
☐ Yes  ☐ No
If no, please explain:..........................................................................................................

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes  3 = Will consider  2 = No  1 = Already doing  N/M = LO not met  N/A = Not applicable

As a result of this activity, I will be able to:

- Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings..................................................4 3 2 1 N/M N/A
- Develop a plan to manage the side effects associated with systemic therapies to support quality of life and continuation of treatment. .............................................4 3 2 1 N/M N/A
- Recall the recent FDA approval of neoadjuvant pertuzumab, and consider this therapeutic approach when evaluating appropriate patients with HER2-positive early breast cancer..................................................4 3 2 1 N/M N/A
- Develop an evidence-based algorithm for the initial and long-term treatment of localized and advanced estrogen receptor-positive breast cancer.............................................4 3 2 1 N/M N/A
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.............................................4 3 2 1 N/M N/A
What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and editor for this educational activity

<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Olson, MSN, RN, CNP</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Denise A Yardley, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

Other comments about the faculty and editor for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: ............................................. Specialty: .............................................

Professional Designation:
☐ MD ☐ DO ☐ PharmD ☐ NP ☐ CNS ☐ RN
☐ PA ☐ Other .............................................

Street Address: ............................................. Box/Suite: .............................................

City, State, Zip: .............................................

Telephone: ............................................. Fax: .............................................

Email: .............................................

Signature: ............................................. Date: .............................................

The expiration date for this activity is July 2016. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ONUBreast115/CNE.